Bristol Myers Squibb...announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. (Businesswire) - Oct 19, 2026 - "Late-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01); Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, from ROSETTA Lung-107 in metastatic non-small cell lung cancer....Long-term survival results evaluating Opdivo in combination with Yervoy in a Phase 3 late-breaking oral presentation."
dMMR • Late-breaking abstract • P2 data • P3 data • Colorectal Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Non Small Cell Lung Cancer
|